EUVIMEDEUVIMED entdecken
Crossref

1331-OR: Hepatic IRS1 as a Therapeutic Target in Metabolic Dysfunction–Associated Liver Disease (MASLD): AI/ML-Driven Genetic Discovery and In Vivo Therapeutic Validation

SANTHOSH SATAPATI, DAVID LLOYD

Diabetes · 08.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1331-or ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 08.06.2026. Verfasst von SANTHOSH SATAPATI und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: MASLD is a common polygenic condition, but current GWASs have only identified 14 loci due to a lack of scalable, clinically relevant phenotypes.

Methods

Using machine learning on four UKBB data modalities (MRI, DXA, plasma metabolites, blood biomarkers; n=25,474 to 262,927), we predicted liver fat (LF) and adipose tissue volume (ATV), increasing statistical power. A GWAS of LF, adjusting for ATV, identified liver-specific genes. Liver-targeted siRNAs validated key targets in vitro and in vivo in mice and monkeys.

Results

GWAS identified 480 loci linked to LF accumulation, showing strong genetic correlation with predicted LF (R2 = 0.79-0.97), and MASLD (R2 = 0.73-0.87). Novel de novo lipogenesis (DNL) genes were found, with IRS1 being the strongest association (p = 2 x 10-82) and supported across all four modalities. A potent, selective liver-targeted siRNA against IRS1 (IC50~0.04 nM) suppressed lipid accumulation in human hepatocytes. In DIO mice a single dose (0.3-10 mg/kg) reduced hepatic IRS1 expression (85%), DNL (59%) and triglycerides (45%) after one month, significantly improving NAS score (2.2 ± 0.2 vs. vehicle 4.3 ± 0.2, p = 0.0002). Cynomolgus monkeys (3 and 10 mg/kg) showed sustained hepatic IRS1 reduction for 28 days without affecting glucose homeostasis.

Conclusion

Liver-targeted siRNA effectively targets IRS1, showing efficacy and tolerability in preclinical MASLD models. Disclosure S. Satapati: Stock/Shareholder; Current; insitro. D. Lloyd: None.

Zitieren

APA

SATAPATI, S., & LLOYD, D. (2026). 1331-OR: Hepatic IRS1 as a Therapeutic Target in Metabolic Dysfunction–Associated Liver Disease (MASLD): AI/ML-Driven Genetic Discovery and In Vivo Therapeutic Validation. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1331-or

Vancouver

SATAPATI S, LLOYD D. 1331-OR: Hepatic IRS1 as a Therapeutic Target in Metabolic Dysfunction–Associated Liver Disease (MASLD): AI/ML-Driven Genetic Discovery and In Vivo Therapeutic Validation. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1331-or

BibTeX
@article{SATAPATI2026,
  author = {SATAPATI, SANTHOSH and LLOYD, DAVID},
  title = {1331-OR: Hepatic IRS1 as a Therapeutic Target in Metabolic Dysfunction–Associated Liver Disease (MASLD): AI/ML-Driven Genetic Discovery and In Vivo Therapeutic Validation},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1331-or}
}
Kostenlos starten →